Printer Friendly

DAVID ROBINSON JOINS BOARD OF DIRECTORS OF IDEC PHARMACEUTICALS

 DAVID ROBINSON JOINS BOARD OF DIRECTORS OF IDEC PHARMACEUTICALS
 LA JOLLA and MOUNTAIN VIEW, Calif., Jan. 16 /PRNewswire/ -- David E. Robinson, the new president and chief executive officer of Ligand Pharmaceuticals and former chief operating officer of Erbamont, has been elected to the board of directors of IDEC Pharmaceuticals Corp. (NASDAQ: IDPH). He replaces Ivor Royston, M.D., who will continue to serve the company as a consultant and a member of the Scientific Advisory Board.
 "David Robinson's addition to our board of directors is a reflection of IDEC's growing emphasis on becoming a fully integrated pharmaceutical firm," noted William H. Rastetter, Ph.D., company president and chief executive officer. "He has 19 years of pharmaceutical industry experience and has an operations perspective that is important to our transition from a research and development company.
 "While Ivor Royston will be leaving our board of directors, we are delighted that he will continue to serve IDEC in a research and development capacity," Dr. Rastetter added. "Dr. Royston was one of IDEC's co-founders and has been a board member since our inception. His expert advice and perspective have proven invaluable over the years."
 Robinson, age 43, became president and chief executive officer of Ligand Pharmaceuticals in November 1991. Ligand is a privately held company applying intracellular receptor technology to the discovery and development of human pharmaceuticals.
 Prior to joining Ligand, Robinson was chief operating officer of Erbamont, a multinational pharmaceutical company with 9,000 employees, a market focus on anti-cancer, cardiovascular and anti-infective drugs, and worldwide annual sales of $1 billion. He previously served as president of Adria Laboratories, Erbamont's North American subsidiary. Robinson also worked for more than 10 years at Abbott Laboratories, holding various executive positions in Abbott's European, Latin American, Pacific and Far East operations.
 IDEC Pharmaceuticals, which operates out of facilities in Mountain View and La Jolla, is a leader in the development of immunologically active monoclonal antibodies for therapeutic applications. The company has four products in ongoing human clinical studies and other products in preclinical testing and research and development. These products are intended to address severe or life-threatening diseases, including immune system cancers (lymphomas and leukemias), malignant melanoma, HIV infection and autoimmune disorders.
 -0- 1/16/92
 /CONTACT: Clifford Orent, senior VP and COO of IDEC Pharmaceuticals, 415-940-1200/
 (IDPH) CO: IDEC Pharmaceuticals ST: California IN: MTC SU: PER


AL-CH -- SD001 -- 0425 01/16/92 10:42 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 16, 1992
Words:401
Previous Article:HAWKINS, PRINCE NAMED TO BOARD OF TRUST COMPANY OF GEORGIA
Next Article:COMPTEK RESEARCH, INC. ANNOUNCES DIVIDEND
Topics:


Related Articles
IDEC PHARMACEUTICALS PROMOTES PHILLIP SCHNEIDER TO VICE PRESIDENT, FINANCE AND ADMINISTRATION
KENNETH WOOLCOTT PROMOTED TO GENERAL COUNSEL AT IDEC PHARMACEUTICALS
ANTONIO J. GRILLO-LOPEZ JOINS IDEC PHARMACEUTICALS AS VICE PRESIDENT, MEDICAL AND REGULATORY AFFAIRS
ANTONIO J. GRILLO-LOPEZ JOINS IDEC PHARMACEUTICALS AS VICE PRESIDENT, MEDICAL AND REGULATORY AFFAIRS
NABIL HANNA PROMOTED TO SENIOR VICE PRESIDENT, RESEARCH AND PRECLINCIAL DEVELOPMENT AT IDEC PHARMACEUTICALS
WILLIAM ROHN JOINS IDEC PHARMACEUTICALS AS SENIOR VICE PRESIDENT, COMMERCIAL AND CORPORATE DEVELOPMENT
DAVID LUDVIGSON JOINS IDEC PHARMACEUTICALS AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER
KENNETH WOOLCOTT PROMOTED TO VICE PRESIDENT, GENERAL COUNSEL & LICENSING EXECUTIVE OF IDEC PHARMACEUTICALS
IDEC PHARMACEUTICALS APPOINTS PHILLIP SCHNEIDER CHIEF FINANCIAL OFFICER
IDEC PHARMACEUTICALS PROMOTES ANTONIO J. GRILLO-LOPEZ TO SENIOR VICE PRESIDENT, MEDICAL AND REGULATORY AFFAIRS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters